Korea Institute of Science and Technology

Sogang University Research Foundation

Hee-Seup Kil

Dae-Yoon Chi

Sang-Yoon Kim

Ick-Chan Kwon

Kui-Won Choi

Hyun-Ju Sung

Kwang-Meyung Kim

Beom-Suk Lee

Ju-Hee Ryu

Jong-Min Kim

Byoung-Se Lee

Cheol-Soo Lee

Eun-Young Heo

The present invention relates to an anticancer prodrug consisting of peptide of acetyl-SEQ ID NO: 1-linker-anticancer drug. The anticancer prodrug effectively provides an anticancer drug unstable in acid or base, such as doxorubicin, in a form of prodrug. Thus, the anticancer prodrug exists as a non-toxic inactive form when administered into the body, but effectively releases the anticancer drug as an active ingredient in the target area in the presence of caspase activated by radiation or UV treatment after administered into the body. Accordingly, the anticancer drug exhibits selective anticancer effects on cancer cells, thereby maximizing the therapeutic effect and minimizing the side-effects of chemotherapy.

Anticancer prodrug activated by radiation or ultraviolet treatment and use thereof

The present invention relates to an anticancer prodrug consisting of peptide of acetyl-SEQ ID NO: 1-linker-anticancer drug. The anticancer prodrug effectively provides an anticancer drug unstable in acid and base, such as doxorubicin, in a form of prodrug. Thus, the anticancer prodrug exists as a non-toxic inactive form when administered into the body, but effectively releases the anticancer drug as an active ingredient in the target area in the presence of caspase activated by radiation or UV treatment after administered into the body. Accordingly, the anticancer drug exhibits selective anticancer effects on cancer cells, thereby maximizing the therapeutic effect and minimizing the side-effects of chemotherapy.

Anticancer prodrugs activated by radiation or ultraviolet treatment and use thereof

Method and apparatus for synthesizing an F-18 labeled radioactive pharmaceutical by labeling a precursor with an F-18 radioactive isotope, by reacting the labeled precursor to obtain a labeled pharmaceutical, by separating impurities from the labeled pharmaceutical to provide a purified labeled pharmaceutical, and by collecting the purified labeled pharmaceutical. The apparatus includes a labeling cartridge that contains the precursor, receives the isotope, and causes a labeling reaction to provide the labeled precursor; a synthesizing container that receives the labeled precursor, receives at least one reagent effective to hydrolyze the labeled precursor, and within which the labeled precursor undergoes a hydrolysis reaction to provide the labeled pharmaceutical; and a separation cartridge that receives the labeled pharmaceutical, and contains a polymer compound that separates impurities into polar compounds and nonpolar compounds to provide the purified labeled pharmaceutical. The labeling and separation cartridges may be contained in a removable cassette.

Apparatus and method for synthesizing F-18 labeled radioactive pharmaceuticals

Growing community of inventors

Seoul, South Korea

Hee-Seup Kil